REFERENCES
- Allen A., Bygate E., Oliver S., Johnson M., Ward C., Cheon A. J., Choo Y. S., Kim I. C. Pharmacokinetics and tolerability of gemifloxacin (SB-265805) after administration of single oral doses to healthy volunteers. Antimicrob. Agents Chemother 2000; 44: 1604–1608, [INFOTRIEVE], [CSA]
- Ball P. Quinolone-induced QT interval prolongation: a not-so-unexpected class effect. J Antimicrob. Chemother 2000; 45: 557–559, [INFOTRIEVE], [CSA], [CROSSREF]
- Ben-David J., Zipes D. P. Torsaes de pointes and proarrhythmia. Lancet 1993; 341: 1578–1582, [INFOTRIEVE], [CSA], [CROSSREF]
- Chiba K., Sugiyama A., Satoh Y., Shiina H., Hashimoto K. Proarrhythmic effects of fluoroquinolone antibacterial agents: in vivo effects as physiologic substrate for torsades. Toxicol. Appl. Pharmacol 2000; 169: 8–16, [INFOTRIEVE], [CSA], [CROSSREF]
- Curran M. E., Splawski I., Timothy K. W., Vincent G. M., Green E. D., Keating M. T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795–803, [INFOTRIEVE], [CSA], [CROSSREF]
- Hagiwara T., Sotoh S., Kasai Y., Takasuna K. A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. Jpn. J. Pharmacol 2001; 87: 231–234, [INFOTRIEVE], [CSA], [CROSSREF]
- Jaillon P., Morganroth J., Brumpt I., Talbot G., Sparfloxacin Safety Group. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J. Antimicrob. Chemother 1996; 37(Suppl. A)161–167, [INFOTRIEVE], [CSA]
- Kang J., Wang L., Chen X. L., Triggle D. J., Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol. Pharmacol 2001; 59: 122–126, [INFOTRIEVE], [CSA]
- Kozawa O., Uematsu T., Matsuno H., Niwa M., Nagashima S., Kanamaru M. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects. Antimicrobial. Agents Chemother 1996; 40: 2824–2828, [CSA]
- Lipsky B. A., Baker C. A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin. Infect. Dis 1999; 28: 352–364, [INFOTRIEVE], [CSA]
- Morganroth J., Hunt T., Dorr M. B., Magner D., Talbot G. H. The cardiac pharmacodynamics of therapeutic doses of sparfloxacin. Clin. Ther 1999a; 21: 1171–1181, [INFOTRIEVE], [CSA], [CROSSREF]
- Morganroth J., Talbot G. H., Dorr M. B., Johnson R. D., Geary W., Magner D. Effects of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QTc interval). Clin. Ther 1999b; 21: 818–828, [INFOTRIEVE], [CSA], [CROSSREF]
- Nakagawa T., Ishigai M., Kato M., Hayakawa N., Kinoshita H., Okutomi T., Ohkubo K., Okazaki A. Pharmacokinetics of the new fluoroquinolone balofloxacin in mice, rats, and dogs. Arzneimittelforschung 1995; 45(6)719–22, [INFOTRIEVE], [CSA]
- Obana M., Irimajiri S., Tomizawa I., Takizawa Y., Sakamoto Y., Nitta Y., Tsunoda T., Fukuda H., Yamaguchi T., Masuda G. l. Clinical study of balofloxacin on infectious enteritis and assessment of the fecal drug concentration and intestinal microbial flora in patients with infectious enteritis. Research group of balofloxacin on infectious enteritis. Kansenshogaku Zasshi 1995; 69(9)991–1006, [INFOTRIEVE], [CSA]
- Sanguinetti M. C. Dysfunction of delayed rectifier potassium channels in an inherited cardiac arrhythmia. Ann. N.Y. Acad. Sci 1999; 868: 406–413, [INFOTRIEVE], [CSA], [CROSSREF]
- Stahlmann R., Lode L. Toxicity of quinolones. Drugs 1999; 58(2)37–42, [INFOTRIEVE], [CSA]
- Whitney G. G., Fawley M. M., Hadler J., Harrison L. H., Lexau C., Renigold A., Lefkowitz L., Cieslak P. R., Certron M., Zell E. R., Jorgensen J. H., Schuchat A. Increasing prevalence of multidrug-resistance Streptococcus pneumoniae in the United States. N. Engl. J. Med 2000; 343: 1917–1924, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]